ASX ANNOUNCEMENT

ASX SMIDcaps 2025 Conference - Presentation

MELBOURNE, Australia (24 September 2025) – Lumos Diagnostics (ASX: LDX), ("Lumos" or the "Company") a leader in rapid, point-of-care diagnostic technologies, has today lodged a presentation to be delivered by Barrie Lambert, Chief Financial Officer, at the ASX SMIDcaps Conference on Wednesday, 24 September 2025.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics,

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:
Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:
George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne, VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598

Lumos Diagnostics Holdings Limited

ASX SMIDcaps Conference

24 September 2025

Financial information is shown in USD unless otherwise stated.

www.lumosdiagnostics.com

Disclaimer and Important Information

This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company).

The information contained in this document ("Document") has been prepared by Lumos Diagnostics Holdings Limited (referred to as "Lumos" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Lumos periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein.

The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast. The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Lumos business and markets. Such information is generally based on independent market and industry data or research. Lumos has not independently verified and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Non-IFRS financial measures

Recipients should note that certain financial data included in this Document is not recognised under the AAS and is classified as 'non-IFRS financial information' under Regulatory Guide 230 'Disclosing non-IFRS financial information' published by ASIC. The Company believes that this non-IFRS financial information provides useful information to users in measuring the financial performance and condition of Lumos. The non-IFRS financial measures do not have standardised meanings under AAS, and therefore may not be comparable with similarly titled measures presented by other entities, nor should these be interpreted as an alternative to other financial measures determined in accordance with AAS. Investors are cautioned not to place undue reliance on any non-IFRS financial information, ratios and metrics included in this Document.

Lumos develops, manufactures and distributes innovative diagnostic products – delivering actionable information, in real time, at the point-of-care.

Lumos Business Overview

LUMOS DIAGNOSTICS

LUMOS DIAGNOSTICS

COMMERCIAL SERVICES

- Development
- Contract Manufacturing

PRODUCTS

- FebriDx®
- Women's Health

People and capability drive value - able to leverage R&D, IP, manufacturing scale, medical, quality and regulatory skillset across Lumos' Products and Commercial Services business.

Financials Summary

Revenue (US$M)



Gross Profit (US$M) & Margin %



Adjusted EBITDA (US$M)



Financial Highlights

Revenue Growth

US$12.4M

FY25, up 12% YoY.
Products up 46% YoY

Gross Profit & Margin consistent & healthy

US$7.8M

GM at 63% for FY25

EBITDA Loss Reducting with Scale

US$3.4M

Future revenue growth to drive earnings

LDX Recent Achievements

FebriDx® Journey To Transform The Practice Of Medicine



Future Events

Oct 2025
FebriDx pediatric study to commence

Nov 2025 – Feb 2026
FDA grant of CLIA waiver anticipated

Nov 2025 – Feb 2026
Phase Scientific US$5.0m pre-paid purchase order triggered on CLIA waiver

The Unmet Medical Need – Respiratory Infections in Primary Care

"Patients want answers. Doctors need certainty. FebriDx® delivers both."

FebriDx® point of care test solution

FebriDx® Supports Antibiotic Stewardship and Helps Combat Antimicrobial Resistance

>99%	99% NPV for ruling out bacterial infection	>90%	Differentiates viral vs bacterial infection >90% accuracy	>40%	Of antibiotic prescriptions prescribed for patients with ARIs are unnecessary
	Aids doctors to confidently and appropriately prescribe antibiotics		Result after 10 min. Patients leave with actionable plan of trust	>US$1B	TAM of 80M acute respiratory infection visits per year in the US

Key Priorities

FDA decision on the CLIA waiver for FebriDx® is expected between November 2025 and February 2026.

Implement agreement with PHASE Scientific, advance national insurance payer coverage through our partnership with Pro-spectus, and plan for volume scale-up.

Initiate FebriDx® pediatric study in October – fully funded with US$6.2M by BARDA - addresses important clinical market for 2 -12 yr olds and expands U.S. market by approx. 20%

Deliver on Hologic fFN development milestones - additional milestone 3 studies from Phase 2 & Phase 3 milestones 4 -9

Progress to formal product development on the first Lumos branded women's health diagnostics test

Investor Takeaways

First in Class Product FebriDx® Nearing Major US Breakthrough

- CLIA waiver study exceeded performance targets (99%+ concordance)
- FDA submission lodged 18 Aug 2025, decision expected Nov 2025 - Feb 2026
- FebriDx® protected by a broad global patent estate covering method, device, and biomarkers

Transformational US$317M (A$487M) Distribution Deal

- With PHASE Scientific for the US market over 6 years,[1] assuming FebriDx® granted CLIA waiver and minimum order quantities (MOQ's) are achieved
- Initial US$5M prepaid order triggered at CLIA waiver grant
- One of the largest POC distribution deals for an ASX-listed diagnostics company

Revenue Growth & Margin Strength

- FY25 revenue up 11% to US$12.4M; product sales up 46%
- Gross margin stable at 63%
- EBITDA loss narrowed by 12% to US$3.4M (showing operating leverage as scale builds)

> US$1.0 Billion p.a. TAM for FebriDx®

- CLIA waiver unlocks >80M patient interactions annually in the US
- Proprietary PLA Reimbursement Code (0442U) assigned for FebriDx®
- CMS established rate on CLFS (Clinical Lab Fee Schedule) for FebriDx® at US$41.38 per test

Commercial Services Division

- Licensing/IP agreements add recurring high-margin revenue
- Hologic: US$10M IP licensing completed and US$6.4M development agreement for next-gen fFN women's health test underway
- Additional US$1.5M Aptatek contract going ahead for in-home PKU monitoring

Strong Funding Partnerships, No Debt, No Royalties Payable

- BARDA: US$9.2M non-dilutive funding (CLIA waiver + pediatric study)
- A$5M loan facility available with Tenmile and Ryder Capital (drawdowns at Lomos discretion)

[1]AUD:USD of 0.651 as at 15 July 2025

LUMOS DIAGNOSTICS

Thank You

www.lumosdiagnostics.com